サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1446461

インフルエンザ診断市場規模、シェア、動向分析レポート：検査タイプ別、最終用途別、地域別、セグメント予測、2024年～2030年

Influenza Diagnostics Market Size, Share & Trends Analysis Report By Test Type (RIDT, RT-PCR, Cell Culture), By End-use (Hospitals, POCT, Laboratories), By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
インフルエンザ診断市場規模、シェア、動向分析レポート：検査タイプ別、最終用途別、地域別、セグメント予測、2024年～2030年
出版日: 2024年02月02日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

インフルエンザ診断市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のインフルエンザ診断市場規模は、2024年から2030年にかけて5.78%のCAGRを記録し、2030年までに24億1,000万米ドルに達する見込みです。

感染サーベイランスの増加や慢性疾患の世界の有病率の上昇が、インフルエンザ診断の需要に寄与しています。例えば、2022年9月、102カ国の国立インフルエンザセンターとその他の検査室は、2022年8月22日から2022年9月04日の間に112,017検体以上を検査しました。そのうち3,879検体がインフルエンザウイルス陽性と判定されました。

WHOや米国保健社会福祉省などの国際機関や規制が、感染拡大を抑制するために関与を強めています。これらの組織は、インフルエンザ・ワクチンの包括的な研究開発に取り組んでいます。VIDRL、Sequirus、CDCなど様々な企業が細胞培養ベースのワクチンを開発していることが確認されています。したがって、この戦略的イニシアチブは、細胞培養技術に対する需要の増加を通じて市場にプラスの影響を与える可能性が高いです。

例えば、2022年9月、WHOはヒトインフルエンザウイルスの分離にNIID-MDCKを含む認証細胞株を使用しました。同組織はまた、細胞培養ベースのワクチン候補ウイルスの遺伝子および抗原解析を行った。ワクチン候補は、細胞培養プロトタイプウイルスに対する二方向性ウイルス中和試験または血球凝集阻害試験に合格しており、WHOの推奨に合致しています。細胞培養由来のワクチン候補は、2023年に開発・製造が可能になると予想されています。

COVID-19パンデミックの間、インフルエンザ・ウイルスを監視・検出するサーベイランスは激減しました。同様に、10月から4月にかけてのインフルエンザ関連入院症例にも動向が見られました。例えば、2019年10月から2020年4月にかけて、米国では約19,299件の入院症例が報告されましたが、2020-21年の同月には232件しか報告されなかったため、COVID-19のピーク時には症例が約98％減少したことになります。しかし、WHOは各国にCOVID-19とインフルエンザウイルスの共流行に備えるよう勧告しています。このことは、地域規制がサーベイランス・プログラムを統合し、インフルエンザのワクチン接種キャンペーンを強化することを奨励しています。

インフルエンザを含む感染症の迅速診断の分野で、POCT（Point-of-Care Testing：ポイント・オブ・ケア検査）の利用可能性が高まっていることから、発展途上国におけるインフルエンザ診断の需要が増加すると予想されます。例えば、2022年10月に欧州諸国における感染症のPOCT範囲を評価する研究が実施されました。この調査によると、サーベイランスのもと、POCTはHIVやインフルエンザなど罹患率の大きい感染症に広く使用されています。

インフルエンザ診断市場レポートハイライト

  • 検査タイプ別では、迅速インフルエンザ診断検査（RIDT）分野が市場をリードし、2023年の世界売上高の30.88%を占め、予測期間で最も速いCAGRを示すと予測されます。製品開発や公開会社による新興国市場への使用範囲の拡大など、戦略的イニシアチブの高まりが市場成長を牽引しています。
  • 最終用途別では、病院が2023年の市場収益シェアで最大を占めました。これは、インフルエンザの合併症のリスクを高める喘息やその他の慢性的な健康状態などの基礎疾患の存在が拡大していることに起因しています。
  • 北米が市場を独占し、2023年の市場全体シェアの32.69%を占めました。企業によるインフルエンザ負担に関するデータへのアクセスが増加し、同地域でのサーベイランス検査が増加しているためです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 インフルエンザ診断市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • インフルエンザ診断市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析
    • 価格分析

第4章 インフルエンザ診断市場：検査タイプの推定・動向分析

  • テストタイプの市場シェア、2023年および2030年
  • セグメントダッシュボード
  • 検査タイプ別の世界のインフルエンザ診断市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで
    • RIDT
    • RT-PCR
    • 細胞培養
    • その他

第5章 インフルエンザ診断市場：最終用途推定・動向分析

  • 最終用途市場シェア、2023年および2030年
  • セグメントダッシュボード
  • 最終用途別の世界のインフルエンザ診断市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで
    • 病院
    • POCT
    • 研究所

第6章 インフルエンザ診断市場：地域別の推定・動向分析

  • 地域市場シェア分析、2023年および2030年
  • 地域市場ダッシュボード
  • 世界の地域市場のスナップショット
  • 市場規模と予測トレンド分析、2018年から2030年：
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 会社/競合の分類
  • ベンダー情勢
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • 3M Company
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • Meridian Bioscience, Inc.
    • Quidel Corporation.
    • F. Hoffmann-La Roche Ltd.
    • SA Scientific Ltd
    • SEKISUI Diagnostics
    • Thermo Fisher Scientific, Inc.
    • Hologic, Inc.
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America influenza diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 4 North America influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 5 U.S. influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 6 U.S. influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 8 Canada influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Europe influenza diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 10 Europe influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 11 Europe influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Germany influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 13 Germany influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 14 UK influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 15 UK influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 16 France influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 17 France influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 18 Italy influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 19 Italy influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 20 Spain influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 21 Spain influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 22 Denmark influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 23 Denmark influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Sweden influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 25 Sweden influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Norway influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 27 Norway influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific influenza diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 31 China influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 32 China influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 33 Japan influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 34 Japan influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 35 India influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 36 India influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 37 South Korea influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 38 South Korea influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 39 Australia influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 40 Australia influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 41 Thailand influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 42 Thailand influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Latin America influenza diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 44 Latin America influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 45 Latin America influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 46 Brazil influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 47 Brazil influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Mexico influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 49 Mexico influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 50 Argentina influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 51 Argentina influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 52 MEA influenza diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 53 MEA influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 54 MEA influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 55 South Africa influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 56 South Africa influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 59 UAE influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 60 UAE influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 61 Kuwait influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 62 Kuwait influenza diagnostics market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Influenza diagnostics market: market outlook
  • Fig. 14 Influenza diagnostics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Influenza diagnostics market driver impact
  • Fig. 20 Influenza diagnostics market restraint impact
  • Fig. 21 Influenza diagnostics market strategic initiatives analysis
  • Fig. 22 Influenza diagnostics market: Test Type movement analysis
  • Fig. 23 Influenza diagnostics market: Test Type outlook and key takeaways
  • Fig. 24 RIDT market estimates and forecast, 2018 - 2030
  • Fig. 25 RT-PCR estimates and forecast, 2018 - 2030
  • Fig. 26 Cell Culture market estimates and forecast, 2018 - 2030
  • Fig. 27 Others estimates and forecast, 2018 - 2030
  • Fig. 28 Influenza diagnostics Market: End Use movement Analysis
  • Fig. 29 Influenza diagnostics market: End use movement analysis
  • Fig. 30 Influenza diagnostics market: End use outlook and key takeaways
  • Fig. 31 Hospitals market estimates and forecasts, 2018 - 2030
  • Fig. 32 POCT market estimates and forecasts,2018 - 2030
  • Fig. 33 Laboratories market estimates and forecasts,2018 - 2030
  • Fig. 34 Global influenza diagnostics market: Regional movement analysis
  • Fig. 35 Global influenza diagnostics market: Regional outlook and key takeaways
  • Fig. 36 Global influenza diagnostics market share and leading players
  • Fig. 37 North America market share and leading players
  • Fig. 38 Europe market share and leading players
  • Fig. 39 Asia Pacific market share and leading players
  • Fig. 40 Latin America market share and leading players
  • Fig. 41 Middle East & Africa market share and leading players
  • Fig. 42 North America, by country
  • Fig. 43 North America market estimates and forecasts, 2018 - 2030
  • Fig. 44 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 45 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 46 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 47 UK market estimates and forecasts, 2018 - 2030
  • Fig. 48 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 49 France market estimates and forecasts, 2018 - 2030
  • Fig. 50 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 51 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 52 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 53 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 54 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 55 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 56 China market estimates and forecasts, 2018 - 2030
  • Fig. 57 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 58 India market estimates and forecasts, 2018 - 2030
  • Fig. 59 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 60 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 61 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 62 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 63 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 64 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 65 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 66 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 67 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 68 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 69 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 70 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 71 Market share of key market players- influenza diagnostics market
目次
Product Code: GVR-1-68038-259-4

Influenza Diagnostics Market Growth & Trends:

The global influenza diagnostics market size is expected to reach USD 2.41 billion by 2030, registering a CAGR of 5.78% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing surveillance of the infection and the rising prevalence of chronic diseases around the world are contributing to the demand for influenza diagnostics. For instance, in September 2022, National Influenza Centres and other laboratories from 102 countries tested over 112,017 specimens between 22 August 2022 to 04 September 2022. Out of those, 3,879 tested positive for influenza viruses.

The increasing involvement of international organizations and regulations, such as WHO and the U.S. Department of Health & Human Services to control the spread of infection. The organizations are indulging in comprehensive research and development of a vaccine for influenza. It has been observed that various companies such as VIDRL, Seqirus, and CDC are developing cell culture-based vaccines. Thus, this strategic initiative is likely to have a positive impact on the market through increasing demand for cell culture technology.

For instance, in September 2022, WHO used a certified cell line including NIID-MDCK for isolating the human influenza virus. The organization also performed genetic and antigenic analysis on the cell culture-based candidate vaccine viruses. The vaccine candidates have passed two-way virus neutralization tests or hemagglutination inhibition against the cell culture prototype viruses and match the recommendation by WHO. It is anticipated that cell-culture-derived vaccine candidates will be available for development and production in 2023.

During the COVID-19 pandemic, the surveillance to monitor and detect the influenza virus drastically decreased. Similarly, the trend was witnessed in flu-related hospitalization cases between October to April. For instance, from October 2019 to April 2020, approximately 19,299 cases of hospitalization were reported in the U.S. While in the same months in 2020-21, only 232 cases were reported, hence, approximately 98% fall in the cases during the peak of COVID-19. However, WHO recommended countries be ready for the co-circulation of COVID-19 and influenza viruses. This encourages the regional regulations to integrate the surveillance program and step-up vaccination campaigns for flu.

The growing availability of point-of-care testing (POCT) in the area of rapid diagnostics of infectious diseases including flu, is expected to increase the demand for influenza diagnostics in developing countries. For instance, a study was conducted in October 2022, to assess the POCT scope for infectious diseases in European countries. As per the study, under surveillance, POCT is widely used for infectious diseases with significant incidence rates, such as HIV and flu.

Moreover, at the global level, flu activity is considerably low. As per the September 2022 report by WHO, the South African region has witnessed a significant rise in flu activity in the past few weeks, and majorly with influenza B viruses were reported. However, in regions such as Central Asia and Northern Africa, no detection of flu was reported. Decreasing incidence rates is anticipated to impact the growth of the market through low product development by companies.

Influenza Diagnostics Market Report Highlights:

  • By test type, Rapid influenza diagnostics tests (RIDTs) segment led the market and accounted for 30.88% of the global revenue in 2023 and is expected to exhibit the fastest CAGR over the forecast period. Owing to the increasing strategic initiatives such as product development and expanding the scope of usage to public events by the companies, hence, driving the market growth
  • By end-user, the hospitals accounted for largest market revenue share in 2023. This is attributed to the growing presence of underlying medical conditions such as asthma and other chronic health conditions, which increases the risk of flu complications
  • North America dominated the market and accounted for a 32.69% share in 2023 of the overall market share. Owing to the increasing accessibility of data on the influenza burden to the companies, and rising surveillance testing in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Test Type
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test Type outlook
    • 2.2.2. End Use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Influenza Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising geriatric population
      • 3.2.1.2. Increasing prevalence of diseases
      • 3.2.1.3. Government initiatives to counter influenza
      • 3.2.1.4. Technological advancements
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Product safety and high development cost
  • 3.3. Influenza Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis

Chapter 4. Influenza Diagnostics Market: Test Type Estimates & Trend Analysis

  • 4.1. Test Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Influenza Diagnostics Market by Test Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. RIDT
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. RT-PCR
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Cell Culture
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Influenza Diagnostics Market: End-Use Estimates & Trend Analysis

  • 5.1. End-Use Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Influenza Diagnostics Market by End Use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Hospitals
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 5.4.2. POCT
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Laboratories
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Influenza Diagnostics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Mexico
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/ reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. 3M Company
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Abbott Laboratories
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Becton, Dickinson and Company
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Meridian Bioscience, Inc.
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Quidel Corporation.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. F. Hoffmann-La Roche Ltd.
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. SA Scientific Ltd
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. SEKISUI Diagnostics
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Thermo Fisher Scientific, Inc.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Hologic, Inc.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives